Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of the efficacy and long-term safety of LUM001 (maralixibat) in PFIC
2013-003833-14Phase 2Completed
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of maralixibat in progressive familial intrahepatic cholestasis (PFIC), sponsored by Mirum Pharmaceuticals, Inc. Primary endpoint: Change in fasting serum bile acids at Week 13. Started Nov 2013; status: completed.
02
Drugs
maralixibat
03
Conditions
progressive familial intrahepatic cholestasis (PFIC)
Beyond the preview
Go deeper on 2013-003833-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003833-14.